Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A
Open Access
- 1 July 2009
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 17 (7), 1145-1154
- https://doi.org/10.1038/mt.2009.35
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII–based clotsBlood, 2008
- Gene therapy for haemophiliaBritish Journal of Haematology, 2008
- Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimensBlood, 2007
- Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatmentJournal of Thrombosis and Haemostasis, 2007
- Lentivirus‐mediated platelet‐derived factor VIII gene therapy in murine haemophilia AJournal of Thrombosis and Haemostasis, 2007
- Efficient expression of a transgene in platelets using simian immunodeficiency virus‐based vector harboring glycoprotein Ibα promoter:in vivomodel for platelet‐targeting gene therapyThe FASEB Journal, 2006
- Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIIIJournal of Thrombosis and Haemostasis, 2003
- Recombinant factor VIII expression in hematopoietic cells following lentiviral transductionGene Therapy, 2003
- Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vectorBlood, 2003
- Characterization of the human factor VIII geneNature, 1984